Topotecan IT

Phase 1Small molecule

CC17 Council

Topotecan IT is one of 16 small molecule programs targeting CNS Embryonal Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CNS Embryonal TumorRecruiting

CNS Embryonal TumorPhase 1

Recruiting

Competition

Competitive Landscape

15 competitors in CNS Embryonal Tumor

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 1

1 2

Tepadina

Jazz Pharmaceuticals

Phase 1

1 3

Nolvadex

AstraZeneca

Phase 1

1 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 6

Vepesid

AAvyxa

Phase 1

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 8

Mesnex

BBaxter Healthcare Corporation

Phase 1

1 9

Neupogen

EEastern Cooperative Oncology Group

Phase 1

1 10

Paraplatin

AAvyxa

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1Recruiting

CNS Embryonal Tumor

NCT06942039

Clinical

Trials by Indication[1]

CNS Embryonal Tumor1 trial

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topotecan IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topotecan IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topotecan IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — C17 Council company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CC17 Council

Topotecan IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

CNS Embryonal Tumor1 trial

References

Drug Info

Quick Facts

Related News